Alzheimer disease
Diffusion tensor imaging
Ioflupane
Magnetic resonance imaging
Tomography (emission-computed
single-photon)
Journal
European radiology experimental
ISSN: 2509-9280
Titre abrégé: Eur Radiol Exp
Pays: England
ID NLM: 101721752
Informations de publication
Date de publication:
04 05 2020
04 05 2020
Historique:
received:
12
11
2019
accepted:
06
03
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
29
4
2021
Statut:
epublish
Résumé
Assessment of nigrostriatal degeneration is a key element to discriminate between dementia with Lewy bodies (DLB) and Alzheimer disease (AD), and it is often evaluated using ioflupane ( A nigroputaminal bundle mask was delineated on 12 healthy volunteers (HV) and applied to MRI diffusion-weighted data of 18 subjects with DLB, 21 subjects with AD and another group of 12 HV. The correlation between nigroputaminal fractional anisotropy (FA) values and DLB patients showed a higher nigroputaminal FA values compared with both AD and HV-controls groups (p = 0.001 for both comparisons), while no difference was observed between HV-controls and AD groups (p = 0.450); at ROC analysis, the area under the curve for the discriminating DLB and AD subjects was 0.820; FA values correlated with In DLB, nigroputaminal degeneration could be reliably assessed on MRI diffusion scans using a mask of nigroputaminal bundle trajectory. Nigroputaminal FA in DLB patients correlated with
Sections du résumé
BACKGROUND
Assessment of nigrostriatal degeneration is a key element to discriminate between dementia with Lewy bodies (DLB) and Alzheimer disease (AD), and it is often evaluated using ioflupane (
METHODS
A nigroputaminal bundle mask was delineated on 12 healthy volunteers (HV) and applied to MRI diffusion-weighted data of 18 subjects with DLB, 21 subjects with AD and another group of 12 HV. The correlation between nigroputaminal fractional anisotropy (FA) values and
RESULTS
DLB patients showed a higher nigroputaminal FA values compared with both AD and HV-controls groups (p = 0.001 for both comparisons), while no difference was observed between HV-controls and AD groups (p = 0.450); at ROC analysis, the area under the curve for the discriminating DLB and AD subjects was 0.820; FA values correlated with
CONCLUSIONS
In DLB, nigroputaminal degeneration could be reliably assessed on MRI diffusion scans using a mask of nigroputaminal bundle trajectory. Nigroputaminal FA in DLB patients correlated with
Identifiants
pubmed: 32363488
doi: 10.1186/s41747-020-00153-6
pii: 10.1186/s41747-020-00153-6
pmc: PMC7196565
doi:
Substances chimiques
Iodine Radioisotopes
0
Tropanes
0
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane
155797-99-2
Iodine-123
8YWR746RPQ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Références
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Comput Methods Programs Biomed. 2010 Jun;98(3):278-84
pubmed: 19818524
Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1240-53
pubmed: 17287959
Ann Neurol. 2019 May;85(5):715-725
pubmed: 30805951
Neuroimage Clin. 2017 Jul 25;16:222-233
pubmed: 28794981
Neuroimage. 2014 Oct 1;99:498-508
pubmed: 24956065
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Brain Res Bull. 1983 Mar;10(3):385-90
pubmed: 6189566
Hum Brain Mapp. 2011 Mar;32(3):461-79
pubmed: 21319270
Neuroimage. 2010 Sep;52(3):1059-69
pubmed: 19819337
PLoS One. 2018 Jan 10;13(1):e0189804
pubmed: 29320500
Brain Struct Funct. 2015 Nov;220(6):3369-84
pubmed: 25134682
Radiology. 2015 May;275(2):430-7
pubmed: 25602507
J Neurol. 2017 Sep;264(9):1865-1874
pubmed: 28730570
Curr Opin Neurol. 2006 Aug;19(4):379-85
pubmed: 16914977
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):565-73
pubmed: 23232506
Sci Rep. 2015 Dec 01;5:17283
pubmed: 26619969
Lancet Neurol. 2004 Jan;3(1):19-28
pubmed: 14693108
Neuroimage. 2009 Jul 15;46(4):958-66
pubmed: 19332141
Neurology. 2001 Apr 10;56(7):926-33
pubmed: 11294931
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Q J Nucl Med Mol Imaging. 2013 Dec;57(4):391-400
pubmed: 23752689
Mov Disord. 2017 Dec;32(12):1738-1747
pubmed: 29119593
J Med Invest. 2005 Aug;52(3-4):186-90
pubmed: 16167537
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Parkinsonism Relat Disord. 2018 Jun;51:55-60
pubmed: 29525556
Lancet Neurol. 2007 Apr;6(4):305-13
pubmed: 17362834
Mov Disord. 2005 Aug;20 Suppl 12:S11-20
pubmed: 16092075